Get started

HIMS

Another Buying Opportunity on $HIMS! 60% UpsideNYSE:HIMS 💊 We are only half way through the week and this is me telling you that THIS IS ANOTHER BUYING OPPORTUNITY! I said the same thing when we had the Short Attack and flush to $19. What you don't realize is that the Wr% at the top of the chart ran up into the barrier of the Williams Consolidation Box and now needs to create it's support and bounce in order to form the BOX. I still believe that's $30 (meaning we wick back above it before weeks end). Whether we do or don't doesn't really matter in the longer term (weeks/months). The downside on the Wr% is limited as well due to the rising trendline (Arrow) we are on since September. If we fall to that I strongly believe we get a bounce off of it, thus creating the box there or where we currently are at. The reason this is a buying opportunity and shouldn't matter to the majority of you is because IMO it will be at $40+ before EOY! Do what you want but I'm cashing in on my Covered Call Premium and Buying more! Not Financial Advice.
NYSE:HIMSLong
by RonnieV29
8
UPDATE for the Markets and Active H5 TradesUPDATE for the Markets and Active H5 Trades 🎂 Today is my oldest sons second birthday. We already celebrated this morning, had birthday donuts and opened gifts. Got my market time in and now... I'm logging off for the day and going to be with him on his special day. Especially after the scary times we've been through with him the last two weeks. Family First ♥️ See you all tomorrow! Here's a last minute 🎁 from my son to you. Updates👇
COINBASE:ETHUSDLong
by RonnieV29
8
$HIMS : YOU DON'T OWN ENOUGH OF THIS NAME HEADING INTO EARNINGS!NYSE:HIMS WHY YOU SHOULD BUY BEFORE EARNINGS. In this video, we talk about: 1.) Why the stock is crashing 2.) Why everything on the Technicals/ Fundamentals point to a STRONG BUY. 3.) My earnings prediction & fair value Thanks for watching! I know it was a longer video, but I always want to be thorough. Comment below if you like this type of content or if your not a fan of videos and rather have posts. NASDAQ:SOFI REPEAT INBOUND! NFA #BuyingOpportunity #BuyTheDip
NYSE:HIMSLong
by RonnieV29
7
$HIMS THE NEXT EXPLOSIVE RETAIL STOCK! NYSE:HIMS THE NEXT EXPLOSIVE RETAIL STOCK! 3 Reasons Why in this Video: 📹 1⃣ My "High Five Trade Setup" strategy 2⃣ Massive Cup N Handle Pattern, 88%+ measured move. 3⃣ Review my "HOMEMADE" Valuation Metric for NYSE:HIMS , showing us a fair value of $35! Video analysis 1/5 dropping today. Stay tuned!🔔 Like ♥️ Follow 🤳 Share 🔂 X Account in Bio Comment what stock you want to see charting analysis on below. Not financial advice. NASDAQ:TSLA NASDAQ:SOFI NYSE:PLTR NASDAQ:NVDA AMEX:IWM NASDAQ:QQQ AMEX:SPY NASDAQ:IBRX NASDAQ:WULF NASDAQ:UPXI #TradingSignals #TradingTips #options #optiontrading #StockMarket #stocks #Retail
NYSE:HIMSLong
by RonnieV29
5
$HIMS IS HIM! BRING ON EARNINGS MONDAY! BULL FLAG SUCCESSFUL RETEST ON NYSE:HIMS We are heading into earnings Monday morning, I'm confident! My "HIGH FIVE SETUP" is pointing to $25+ while... My "Valuation Analyzer" is pointing to $35 Fair Value. Been on a heater; lets see if we stay hot! A full, in-depth video from October 30th discusses this setup, technicals, fundamentals, and valuation, which are linked to this idea. Enjoy! What is your HIMS price prediction after earnings? LIKE l FOLLOW l SHARE
NYSE:HIMSLong
by RonnieV29
3
$HIMS | Allocation | Market Exec |Technical Confluences: - Price action is near the 50% Fibo retracement area - Price action have bounced off the 200 MA (Red) and has a valid Resistance Trendline with an Interest Zone nearby - Stochastics is inn Oversold conditions in the Daily & Weekly timeframes - Elliot Wave 4 seems to be completing at the 50% Fibo line and aim for the 100% Fibo Extension line @ 29.51 Fundamental Confluences: - Telemedicine with US being a focus market is great as healthcare issues seems to be increasing; demographics start to shift right - The main health markets that they target are issues that many in the society prefer to remain anonymous about and telemedicine solves that for them - One negative would be the high expenses they are spending on A&P budgets, a drag but overtime, we can see the impact of what they have been pushing all these while ________________________________ Putting NYSE:HIMS as part of my medical/health category of my portfolio. Will start my first allocation now and look at adding more into it if price moves into 50% - 61% Fibo range (Interest Zone). Remember, DYOR. ________________________________ Boosts 🚀, Follows ✌️, Shares 🙌 & Comments ✍️ are much appreciated! If you have any ideas or charts, do share them in the 'Comments' section below and we can discuss our perspectives to improve or strengthen our strategies. If you want something analyzed, do drop me a DM. :D ________________________________ Disclaimer: The above suggestion is an personal opinion in general and does not constitute as investment advice. Any decisions taken based on the above suggestion is purely your own risks. DYOR.
NYSE:HIMSLong
by weekendanalyst
HIMS - June 24 Qullamaggie Breakout and Episodic PivotI believe the inclusion of the compounded GLP-1 drug as part of their product offerings will driving strong sales and membership numbers in the next few months. 1) Their compounded GLP-1 is significantly cheaper 2) Their platform makes it easier and more accessible to purchase 3) It is lifestyle related so monthly recurring purchases is encouraged 4) HIMS is essentially a DTC business where capturing market share is crucial at this stage. In 2021 it was reported that they spend 48% of their revenue on marketing. As long as they can secure recurring purchases with a solid Average Order Value (AOV), they can gradually reduce and optimise expenses for new acquisitions once they have captured a significant market share. Not to mention the cross sell potential and the lower advertising costs for existing customers This is part of a Qullamaggie Breakout and Episodic Pivot study I am currently conducting Source @moizali - x.com www.triplewhale.com
NYSE:HIMSLong
by Ronin_trader
2
Shares of Hims & Hers Health ($HIMS) Stock Surge 30% Digital pharmacy startup Hims & Hers Health ( NYSE:HIMS ) is introducing compounded GLP-1 weight loss injections, which have been gaining popularity due to supply constraints in the market. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December but did not include GLP-1 medications such as Ozempic and Wegovy. Customers can access the compounded GLP-1 medications via a prescription from a licensed healthcare provider on the Hims & Hers platform. Hims & Hers ( NYSE:HIMS ) CEO Andrew Dudum said that the company is "confident" that customers will be able to access a consistent supply of the compounded medications. The company's oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month. The company expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The GLP-1 market, dominated by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as drugs like Ozempic and Wegovy continue to skyrocket in popularity. The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient's needs. In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available. Hims & Hers ( NYSE:HIMS ) Health's stock price is doing well, thanks to its strong growth and demand for its core products. It has surged by over 30% this year and by more than 112% this year, giving it a market cap of $3.13 billion. Hims & Hers Health's ( NYSE:HIMS ) business released data this month showing that its total revenue soared by 46% in Q1 to over $278 million, and its subscribers roared by 41% to 1.7 million. This performance makes it one of the fastest-growing companies in the US. Hims & Hers ( NYSE:HIMS ) expects revenue growth between $292 million and $297 million in Q2 while the adjusted EBITDA will be between $30 and $30 million. The company focuses on some of the biggest industries globally, including sex, anxiety, weight loss, hair, and skin, each of which has a total addressable market worth billions of dollars. Analysts believe that NYSE:HIMS revenue will jump to over $1.2 billion this year followed by $1.5 billion in 2025, which could help justify its hefty valuation.
NYSE:HIMSLong
by DEXWireNews
HIMS a gender focused health care company LONGHIMS had an excellent earnings report for a small cap company; it is consumer driven quality focused and helps the customer feel good about him/her- self. It does not have any gender orientation agenda nor any obvious political inclinations. On the 120 minute chart, it started a moving averge convergence about a week before earnings. The Greeny TTM squeeze indicator did its thing as the post-earnings action began. I see this stock as a good long to hold into the next earnings and perhaps through it. HIMS is now at its all time high. There is no chart horizontal resistance overhead and traders will note that. I see the bullish momentum continuing perhaps with some healthy ( no pun intended) corrections while underway. Healthcare is considered to be a hot sector for 2024 this small cap seems to be warmed up.
NYSE:HIMSLong
by AwesomeAvani
Short Trade in HIMSThis is a potential short trade that could deliver a nice gain if the market pulls back. I am still focused on buying opportunities, but it never hurts to be prepared for the other side. Some of you may remember this as a stock I was looking to buy a couple months ago. Often times, the best short ideas come from stocks on my long watchlist that fail. HIMS tripled from October to April but began rolling over after a poor earnings report at the beginning of May. Not only did the stock fall on above-average volume, but even a 33% discount has failed to attract buyers. When stocks pull back, they either act as tennis balls (bounce back quickly) or eggs (splat and fail to rally). Buy tennis balls. Sell eggs. HIMS has formed a support shelf near the $8 level. A move below that would trigger a lot of stops, making it an ideal place to sell the stock short.
NYSE:HIMSShort
by rossgivens
2
Breakout Trade in HIMSHIMS is another high growth name. Sales have nearly doubled in each of the last four quarters and losses are steadily declining. HIMS stock got overcooked after rising 195% between October and May, triggering a 30% retracement. This stock also has an “undercut & rally” setup forming. Note the dashed line on the chart above. This was a significant area of resistance previously, so the move below this level last month likely took out a lot of investors. Shares have consolidated in a tight range on low volume for the last two weeks. This is likely support buying as longer-term investors build or add to their positions. I want to see a move above the support/resistance line at 9.50. A move above that price would be my buy trigger. My stop loss would be at 8.70 to risk 8% on the trade.
NYSE:HIMSLong
by rossgivens